News and Announcements
OncoSil Medical Granted UK Central Ethics Approval for Global Clinical Study
- Published April 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that is has been granted UK Central Ethics Approval for its global clinical study programme for pancreatic cancer.
KEY TAKEAWAYS:
- UK Central Ethics Approval has been granted for the global pancreatic clinical study programme;
- This approval initially for Guys and St Thomas’ Hospital London will now facilitate ethics approval for all 5 participating UK study centres;
- This approval will expedite patient recruitment for the UK arm of clinical study;
- In Australia, Westmead Hospital was granted Ethics approval on 28 March.
The Central Ethics Approval granted on 31 March initially covering Guys and St Thomas’ Hospital, London will facilitate ethics approval for all 5 participating centres in the United Kingdom. This in turn will help expedite the patient recruitment process for the UK arm of the clinical study.
The UK centres participating in the global pancreatic clinical study programme are:
Guy’s and St Thomas’ Hospital, London – lead UK study centre
The University of Leicester
The Royal Liverpool
Hammersmith Hospital, London
Addenbrookes Hospital, Cambridge
In Australia, Westmead Hospital, Sydney was granted ethics approval on 28 March and will over the coming weeks finalise preparation to enrol patients into the study programme.
Westmead Hospital is a specialised tertiary referral hospital for the Western Sydney metropolitan area, serving one of the largest growing population areas in the state of New South Wales.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global pancreatic clinical study programme in pancreatic cancer at Guys and St Thomas’ Hospital in London. The Guys and St Thomas’ NHS Trust is a highly regarded cancer centre internationally and is also the lead UK centre for our clinical study programme. The granting of Central Ethics Approval now paves the way for the provision of ethics approval across the other four (4) UK study centres. The granting of ethics approval for Westmead Hospital means that shortly this hospital will join St Vincent’s in Sydney and Monash Health in Melbourne in recruiting patients for the clinical programme. ”
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
